Pilot Study on the Effects of IMOOVE in Parkinson's Disease Patients

Study First Received, September 23,2020
Lead Sponsor: IRCCS San Raffaele (Funder Type: Other)
Conditions
Parkinson Disease
Interventions
Device: IMOOVE
Study Type
Interventional
Status
ongoing, recruiting (30 patients)
Study Duration
2019-05-22 to 2020-12-31
Overview Outcomes Eligibility Locations Investigators No Results
Overview
Official Title
Pilot Study on the Effects of IMOOVE in Parkinson's Disease Patients

Acronym
IMOOVE-PD

Summary
Parkinson's Disease (PD) is one of the most frequent causes of motor dysfunction in aging. It is therefore important to use rehabilitative therapeutic approaches that may prevent the development of motor complications when possible. Imoove® is a device dedicated to rehabilitation and fitness and has the capacity to increase muscle tenfold. The project is focused on quantifying the efficacy of IMOOVE® as a treatment method for improving joint mobility, posture and autonomy in PD.

Detailed Description
The pathogenesis of PD-related postural abnormalities is probably multifactorial as well as widely indefinite, and this could compromise treatment choices and efficacy. In addition to dystonia and rigidity, proprioceptive and sensorimotor disintegration as well as peripheral degenerative processes (myopathy, skeletal and soft tissue changes) have been proposed as causative factors of abnormal trunk postures. When the body is educated in the Elispheric® movement it relearns the original vertebral motion, and postural control necessary for any action by the body, the professional can then perform effective vertebral reeducation. The Elispheric® movements are created by a motorised plate. This unique technology impulses the body through a centrifugal force in three planes. This force trains the body in its natural spirals. The performance result is based on the fact that Imoove restores the all freedom of movement, strength, precision and it works on the basic skeletal posture. It is an exploratory study, in order to verify if the project is adequate, to establish its feasibility and to obtain information that allows to determine the size of the sample of the definitive study, 30 consecutive PD outpatients will be recruited for the IMOOVE® treatment.

Arms
IMOOVE Experimental Patients will undergo IMOOVE® treatment for 6 weeks, two times per week for a total of 12 treatments.

Funder Type
Other

Lead Sponsor
IRCCS San Raffaele

First Received
2020-09-23

Last Updated
2020-10-01

Start Date
2019-05-22

Primary Completion
2020-12-31

Completion Date
2020-12-31

NCT Identifie
NCT04568447

Contact Information
fabrizio stocchi, MD PhD, +39 0652252311, fabrizio.stocchi@sanraffaele.it

Outcomes
Eligibility
Locations
Investigators
No Results